journal article·2024-10-01Open access

Engineered Bacteriophage-Polymer Nanoassemblies for Treatment of Wound Biofilm Infections

Jungmi Park, Muhammad Aamir Hassan, Ahmed Nabawy, Cheng Hsuan Li, Mingdi Jiang, Krupa Parmar, Annika Reddivari, Ritabrita Goswami, Taewon Jeon, Robin Patel, Vincent M. Rotello

ACS Nano· Volume 18· Issue 39

Abstract

The antibacterial efficacy and specificity of lytic bacteriophages (phages) make them promising therapeutics for treatment of multidrug-resistant bacterial infections. Restricted penetration of phages through the protective matrix of biofilms, however, may limit their efficacy against biofilm infections. Here, engineered polymers were used to generate noncovalent phage-polymer nanoassemblies (PPNs) that penetrate bacterial biofilms and kill resident bacteria. Phage K, active against multiple strains of Staphylococcus aureus, including methicillin-resistant S. aureus (MRSA), was assembled with cationic poly(oxanorbornene) polymers into PPNs. The PPNs retained phage infectivity, while demonstrating enhanced biofilm penetration and killing relative to free phages. PPNs achieved 3-log 10 bacterial reduction (∼99.9%) against MRSA biofilms in vitro. PPNs were then incorporated into Poloxamer 407 (P407) hydrogels and applied onto in vivo wound biofilms, demonstrating controlled and sustained release. Hydrogel-incorporated PPNs were effective in a murine MRSA wound biofilm model, showing a 1.5-log 10 reduction in bacterial load compared to a 0.5 log reduction with phage K in P407 hydrogel. Overall, this work showcases the therapeutic potential of phage K engineered with cationic polymers for treating wound biofilm infections.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Bacterial biofilms and quorum sensing · Bacteriophages and microbial interactions · Antimicrobial agents and applications

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Chemistry, University of Massachusetts Amherst, 710 North Pleasant Street, Amherst, Massachusetts 01003, United States

Division of Clinical Microbiology, Department of Laboratory Medicine and Pathology, Mayo Clinic, 200 First Street SW, Rochester, Minnesota 55905, United States

Division of Public Health, Infectious Diseases and Occupational Medicine, Mayo Clinic, 200 First Street SW, Rochester, Minnesota 55905, United States

Funding

National Institute of Allergy and Infectious Diseases · National Institute of Biomedical Imaging and Bioengineering

References (55)

Show source-provided references
1. 10.3389/fpubh.2014.0014510.3389/fpubh.2014.00145 ↗
2. 10.4137/PMC.S1445910.4137/PMC.S14459 ↗
3. 10.1038/s41579-022-00682-410.1038/s41579-022-00682-4 ↗
4. 10.1186/s13756-019-0533-310.1186/s13756-019-0533-3 ↗
5. 10.1038/nrmicro.2016.9410.1038/nrmicro.2016.94 ↗
6. 10.1093/jac/dkq25710.1093/jac/dkq257 ↗
7. 10.1016/j.heliyon.2019.e0219210.1016/j.heliyon.2019.e02192 ↗
8. 10.3390/antibiotics1001000310.3390/antibiotics10010003 ↗
9. 10.3389/fchem.2019.0082410.3389/fchem.2019.00824 ↗
10. 10.1186/s43141-021-00242-y10.1186/s43141-021-00242-y ↗
11. 10.1111/j.1524-475X.2007.00321.x10.1111/j.1524-475X.2007.00321.x ↗
12. 10.1146/annurev-med-080219-12220810.1146/annurev-med-080219-122208 ↗
13. 10.1128/aac.02071-2110.1128/aac.02071-21 ↗
14. 10.1057/s41599-020-0478-410.1057/s41599-020-0478-4 ↗
15. 10.4161/bact.1.2.1459010.4161/bact.1.2.14590 ↗
16. 10.1016/j.clinthera.2020.07.01410.1016/j.clinthera.2020.07.014 ↗
17. 10.1007/s00253-021-11695-z10.1007/s00253-021-11695-z ↗
18. 10.1146/annurev-med-080219-12220810.1146/annurev-med-080219-122208 ↗
19. 10.3389/fphar.2021.69905410.3389/fphar.2021.699054 ↗
20. 10.1038/s41564-017-0050-110.1038/s41564-017-0050-1 ↗
21. 10.1038/s41564-017-0078-210.1038/s41564-017-0078-2 ↗
22. 10.1021/acs.est.6b0423610.1021/acs.est.6b04236 ↗
23. 10.1038/ismej.2017.19010.1038/ismej.2017.190 ↗
24. 10.1016/j.scitotenv.2023.16302710.1016/j.scitotenv.2023.163027 ↗
25. 10.1093/gbe/evaa14610.1093/gbe/evaa146 ↗
26. 10.1128/AEM.01979-2010.1128/AEM.01979-20 ↗
27. 10.1128/JB.00792-1710.1128/JB.00792-17 ↗
28. 10.3390/v1405105710.3390/v14051057 ↗
29. 10.1021/jacs.8b0696110.1021/jacs.8b06961 ↗
30. 10.1002/macp.20220022610.1002/macp.202200226 ↗
31. 10.1039/D3SC90061D10.1039/D3SC90061D ↗
32. 10.1021/acsami.3c0624210.1021/acsami.3c06242 ↗
33. 10.3390/antibiotics1208124010.3390/antibiotics12081240 ↗
34. 10.1021/acs.analchem.6b0375110.1021/acs.analchem.6b03751 ↗
35. 10.1128/AAC.01609-1910.1128/AAC.01609-19 ↗
36. 10.1016/j.apsb.2022.05.00710.1016/j.apsb.2022.05.007 ↗
37. 10.1021/jacs.9b1275910.1021/jacs.9b12759 ↗
38. 10.1021/la200102z10.1021/la200102z ↗
39. 10.1093/ofid/ofad500.176610.1093/ofid/ofad500.1766 ↗
40. 10.1128/AAC.01879-2110.1128/AAC.01879-21 ↗
41. 10.1038/s41467-023-38364-110.1038/s41467-023-38364-1 ↗
42. 10.1039/D1NR04936D10.1039/D1NR04936D ↗
43. 10.1128/AEM.71.4.1836-1842.200510.1128/AEM.71.4.1836-1842.2005 ↗
44. 10.1111/j.1745-4581.2009.00182.x10.1111/j.1745-4581.2009.00182.x ↗
45. 10.1016/j.isci.2021.10228710.1016/j.isci.2021.102287 ↗
46. 10.1128/mBio.01874-1710.1128/mBio.01874-17 ↗
47. 10.3389/fmicb.2018.0234810.3389/fmicb.2018.02348 ↗
48. 10.3390/antibiotics1002013010.3390/antibiotics10020130 ↗
49. 10.1039/D3BM01383A10.1039/D3BM01383A ↗
50. 10.3390/pharmaceutics1112067110.3390/pharmaceutics11120671 ↗
51. 10.1038/srep2411210.1038/srep24112 ↗
52. 10.3390/polym1417362410.3390/polym14173624 ↗
53. 10.1016/j.jconrel.2023.09.00210.1016/j.jconrel.2023.09.002 ↗
54. 10.1002/ame2.1206710.1002/ame2.12067 ↗
55. 10.1371/journal.pone.005923210.1371/journal.pone.0059232 ↗